The Top 5 Biosimilar Articles for the Week of May 3
Here are the top 5 biosimilar articles for the week of May 3, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of May 3, 2021.
Number 5: Representative Carolyn B. Maloney questions the use of pharmaceutical profits to defend against biosimilar competition in recent arguments before the House Subcommittee on Antitrust, Commercial, and Administrative Law.
Number 4: Biosimilars producers reported positive sales trends for biosimilars as the pandemic wears on and said patients still are not visiting doctors in the proportions they did before the start of the health crisis in early 2020.
Number 3: Biocon Biologics reported that their first-quarter revenues were up 26%, to $275.9 million, vs the comparable year-ago quarter, driven largely by the company's biosimilars, research services, and generics businesses.
Number 2: The results of the Voltaire-X trial could persuade the FDA to authorize automatic substitution of the adalimumab biosimilar Cyltezo for its reference product (Humira), investigators believe.
Number 1: Two much-touted bills for biologics and biosimilar advancement were signed into law by President Joe Biden, but the devil is in the details, and whether they are going to have a tangible effect on biosimilar access is debatable.
To read all of these articles and more, visit centerforbiosimilars.com.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.
